Oncolytic viruses: an approved product on the horizon?
作者信息
Bell John
出版信息
Mol Ther. 2010 Feb;18(2):233-4. doi: 10.1038/mt.2009.314.
Abstract
摘要
相似文献
1
Oncolytic viruses: an approved product on the horizon?溶瘤病毒：即将获批的产品？
Mol Ther. 2010 Feb;18(2):233-4. doi: 10.1038/mt.2009.314.
2
Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies.溶瘤病毒：从质量控制到临床研究的监管方面。
Curr Cancer Drug Targets. 2018;18(2):202-208. doi: 10.2174/1568009617666170222142650.
3
Regulatory aspects of oncolytic virus products.溶瘤病毒产品的监管方面。
Curr Cancer Drug Targets. 2007 Mar;7(2):203-8. doi: 10.2174/156800907780058790.
4
Clinical development of oncolytic viruses in China.中国溶瘤病毒的临床开发。
Curr Pharm Biotechnol. 2012 Jul;13(9):1852-7. doi: 10.2174/138920112800958760.
5
Oncorine, the World First Oncolytic Virus Medicine and its Update in China.恩可欣，全球首款溶瘤病毒药物及其中国进展。
Curr Cancer Drug Targets. 2018;18(2):171-176. doi: 10.2174/1568009618666171129221503.
6
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.日本的溶瘤病毒治疗：临床试验的进展和未来展望。
Jpn J Clin Oncol. 2019 Mar 1;49(3):201-209. doi: 10.1093/jjco/hyy170.
7
Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status.溶瘤病毒疗法治疗恶性肿瘤：当前临床现状
Curr Pharm Des. 2019;25(40):4251-4263. doi: 10.2174/1381612825666191104090544.
8
Novel oncolytic viruses: riding high on the next wave?新型溶瘤病毒：在下一波浪潮中高歌猛进？
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):177-83. doi: 10.1016/j.cytogfr.2010.02.012. Epub 2010 Mar 12.
9
Clinical Application of Oncolytic Viruses: A Systematic Review.溶瘤病毒的临床应用：系统评价。
Int J Mol Sci. 2020 Oct 12;21(20):7505. doi: 10.3390/ijms21207505.
10
Current status of clinical trials assessing oncolytic virus therapy for urological cancers.评估溶瘤病毒疗法用于泌尿系统癌症的临床试验现状
Int J Urol. 2017 May;24(5):342-351. doi: 10.1111/iju.13325. Epub 2017 Mar 21.
引用本文的文献
1
Oncogenic Ras inhibits IRF1 to promote viral oncolysis.致癌性 Ras 抑制 IRF1 以促进病毒溶瘤。
Oncogene. 2015 Jul 23;34(30):3985-93. doi: 10.1038/onc.2014.331. Epub 2014 Oct 27.
2
Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.在非人灵长类动物中静脉注射新城疫病毒用于溶瘤病毒疗法是安全的。
Cancer Gene Ther. 2014 Nov;21(11):463-71. doi: 10.1038/cgt.2014.51. Epub 2014 Sep 26.
3
Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.人胰腺腺癌细胞系对溶瘤性新城疫病毒感染的不同反应。
Cancer Gene Ther. 2014 Jan;21(1):24-30. doi: 10.1038/cgt.2013.78. Epub 2014 Jan 3.
4
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.病毒疗法、基因转移和免疫刺激单克隆抗体。
Oncoimmunology. 2012 Nov 1;1(8):1344-1354. doi: 10.4161/onci.21679.
5
Reovirus: a targeted therapeutic--progress and potential.呼肠孤病毒：一种有针对性的治疗药物——进展与潜力。
Mol Cancer Res. 2012 Dec;10(12):1514-25. doi: 10.1158/1541-7786.MCR-12-0157. Epub 2012 Oct 4.
6
Oncolytic viruses in the treatment of cancer: a review of current strategies.溶瘤病毒在癌症治疗中的应用：当前策略综述。
Pathol Oncol Res. 2012 Oct;18(4):771-81. doi: 10.1007/s12253-012-9548-2. Epub 2012 Jun 20.
7
Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.水疱性口炎病毒溶瘤治疗干扰肿瘤相关树突状细胞功能并破坏肿瘤抗原呈递。
J Virol. 2011 Dec;85(23):12160-9. doi: 10.1128/JVI.05703-11. Epub 2011 Sep 14.
8
Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation.p53 的稳定增强了呼肠孤病毒诱导的细胞凋亡和病毒传播，这是通过 p53 依赖性 NF-κB 激活实现的。
Br J Cancer. 2011 Sep 27;105(7):1012-22. doi: 10.1038/bjc.2011.325. Epub 2011 Aug 23.
9
Paramyxovirus entry and targeted vectors for cancer therapy.副粘病毒进入机制及癌症治疗的靶向载体
PLoS Pathog. 2010 Jun 24;6(6):e1000973. doi: 10.1371/journal.ppat.1000973.
本文引用的文献
1
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.编码粒细胞巨噬细胞集落刺激因子的第二代溶瘤性疱疹病毒在不可切除转移性黑色素瘤患者中的II期临床试验。
J Clin Oncol. 2009 Dec 1;27(34):5763-71. doi: 10.1200/JCO.2009.24.3675. Epub 2009 Nov 2.
2
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.溶瘤呼肠孤病毒与顺铂化疗对小鼠恶性黑色素瘤的协同作用
Clin Cancer Res. 2009 Oct 1;15(19):6158-66. doi: 10.1158/1078-0432.CCR-09-0796. Epub 2009 Sep 22.
3
An overview of small-molecule inhibitors of VEGFR signaling.VEGFR信号通路小分子抑制剂概述。
Nat Rev Clin Oncol. 2009 Oct;6(10):569-79. doi: 10.1038/nrclinonc.2009.130. Epub 2009 Sep 8.
4
Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta.人类癌细胞已经特异性地丧失了诱导由肿瘤坏死因子加β干扰素所引发的协同状态的能力。
Cytokine. 2009 Sep;47(3):199-205. doi: 10.1016/j.cyto.2009.06.006. Epub 2009 Jul 28.
5
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.一项关于晚期癌症患者静脉注射3型迪尔林溶瘤呼肠孤病毒的I期研究。
Clin Cancer Res. 2008 Nov 1;14(21):7127-37. doi: 10.1158/1078-0432.CCR-08-0524.
6
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.靶向溶瘤痘病毒JX-594用于难治性原发性或转移性肝癌患者的I期试验
Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19.
7
Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer.基于细胞的溶瘤病毒递送：对抗癌症的生物打击新战略联盟。
Mol Ther. 2007 Apr;15(4):660-5. doi: 10.1038/sj.mt.6300098. Epub 2007 Jan 30.
8
Rescue and propagation of fully retargeted oncolytic measles viruses.完全重新靶向的溶瘤麻疹病毒的拯救与增殖
Nat Biotechnol. 2005 Feb;23(2):209-14. doi: 10.1038/nbt1060. Epub 2005 Jan 30.
Zotero 插件